2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives

Details 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives

2006-07-25

2008-07-08

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S485000

Reexamination Certificate

active

07396853

ABSTRACT:
The present invention relates to compounds of formula I:wherein R1, R2, R3, R4, R5and R6are as defined in the specification and claims, which compounds are active on the GABABreceptor and are useful in the control or prevention of CNS illnesses, especially of illnesses and disorders comprising anxiety, depression, epilepsy, schizophrenia, and cognitive disorders.

REFERENCES:
patent: 0 825 193 (1998-02-01), None
patent: WO 01/56990 (2001-08-01), None
patent: WO 2002/083133 (2002-10-01), None
patent: WO 2005/026208 (2005-03-01), None
S.J.Enna, Expert Opinion on Investigational Drugs, vol. 6, No. 10, 1997, pp. 1319-1325, XP002399755.
K.Hirota, et al., Toxicology Letters, vol. 100-101, 1998, pp. 203-207, XP002403333.
Hill et al., Nature, 290, pp. 149-152, (1981).
Billinton et al. Trends in Neurosci., 24, 277-282, (2001).
Bowery et al., Pharmacol. Rev.. 54, pp. 247-264, (2002).
Vacher et al., Curr. Drug Targets, CNS Neurol. Disord. 2, pp. 248-259, (2003).
Bettler et al., Physiol Rev. 84, pp. 835-867, (2004).
Kaupmann et al., Nature, 386, pp. 239-246, (1997).
Kaupmann et al., Nature, 396, pp. 683-687, (1998).
Pin et al., Pharmaco.. Ther. 98, pp. 325-354, (2003).
Galvez et al., J. Biol. Chem., 275, pp. 41166-41174, (2000).
Havlickova et al., Mol. Pharmacol. 62, pp. 343-350, (2002).
Kniazeff et al.,J. Neurosci., 22, pp. 7352-7361, (2002).
Schuler et al., Neuron, 31, pp. 47-58, (2001).
Peters et al., Neurogenetics, 2, pp. 47-54, (1998).
Gassmann et al., J Neurosci. 24, pp. 6086-6097, (2004).
Misgeld et al., Prog. Neurobiol. 46, pp. 423-462, (1995).
Enna et al., Life Sci, 62, pp. 1525-1530, (1998).
McCarson et al., Neuropharmacology, 38, pp. 1767-1773, (1999).
Brebner et al., Neuropharmacology, 38, pp. 1797-1804, (1999).
Paterson et al., Psychopharmacology, 172, pp. 179-186, (2004).
Breslow et al., Am. J. Psychiatry, 146, pp. 353-356, (1989).
Drake et al., Ann. Pharmacother. 37., pp. 1177-1181, (2003).
Bortolato et al., Psychopharmacology, 171, pp. 322-330, (2004).
Urwyler et al., Mol. Pharmacol., 60, pp. 963-971, (2001).
Pin et al., Mol. Pharmacol.,60, pp. 881-884, (2001).
Binet et al., J Biol Chem., 279, pp. 29085-29081, (2004).
Urwyler et al., J. Pharmacol. Exp. Ther., 307, pp. 322-330, (2003).
Cryan et al., J Pharmacol Exp Ther., 310, pp. 952-963, (2004).
Smith et al., Psychopharmacology, 173, pp. 105-111, (2004).
Knoflach et al., Proc. Natl. Acad. Sci., USA, 98, pp. 13402-13407, (2001).
Wichmann et al., II Farmaco, 57, pp. 989-992, (2002).
Hammerland et al., Mol. Pharmacol., 53, pp. 1083-1088, (1998).
O'Brien et al., J. Pharmaco. Exp. Ther., 309, pp. 568-577 (2004).
Schaffhauser et al., Mol. Pharmacol., 64, pp. 798-810, (2003).
Dyacheno et al., 1989, vol. 4, pp. 923-928 (Translation).
Calver et al., Neuroscience, vol. 100 pp. 155-170 (2000).
Schwarz et al., J. Biol. Chem. vol. 275, pp. 32174-32181 (2000).
Schwarz et al., J. Biol. Chem. vol. 276, Additions and Corrections, p. 9582 (2001).
Uezono et al., J. Pharmacol. Sci. vol. 94, pp. 211-213 (2004).
Mombereau et al., Neuroreport, vol. 16, pp. 307-310 (2005).
Zai et al., Eur. Neuropsychopharmacol, vol. 15, pp. 347-352 (2005).
Zai et al., Am. J. Med. Genet B, (Neuropsychiart. Genet) vol. 134, pp. 25-29 (2005).
Paterson et al., Neuropsychopharmacology, vol. 30, pp. 119-128 (2005).
Bolser et al., Br. J. Pharmacol. vol. 113, pp. 1344-1348 (1994).
Dicpinigaitis et al., J. Clin. Pharmacol. vol 38, pp. 364-367 (1998).
Dicpinigaitis et al., Arch. Phys. Med. Rehabil. vol. 81, pp. 921-923 (2000).
Cange et al., Ailment Pharmacol. Ther. vol. 16, pp. 869-873 (2002).
Lehmann et al., Eur. J. Pharmacol. vol. 448 pp. 67-70 (2002).
Pehrson et al., J. Urol. vol. 168, pp. 2700-2705 (2002).
Sanger et al., Auton Autacoid Pharmacol. vol. 22, pp. 147-154 (2002).
Symonds et al., Eur. J. Pharmacol. vol. 470, pp. 95-97 (2003).
Piqueras et al., Br. J. Pharmacol. vol. 142, pp. 1038-1048 (2004).
Carai et al., Eur. J. Pharmacol. vol. 504, pp. 213-216 (2004).
Mombereau et al., Neuropsychopharmacology, vol. 29, pp. 1050-1062 (2004).
Casiraghi et al., J. C. S., Perkin Trans., 1983 pp. 1649-1651.
Nicolaou, J. Am. Chem. Soc. (2004) vol. 126, pp. 12888-12896.
Choudhury-Mukherjee et al., J. Med. Chem. 2003, vol. 46, pp. 2494-2501.
Porter et al., Br. J. Pharmacol. vol. 128, pp. 13-20 (1999).
Bartlett et al., J. Am. Chem. Soc. 1954, vol. 76, pp. 2349-2353.

Affiliated with

Also associated with

Rating

2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3971323